ReviewNature2019
Why and where an HIV cure is needed and how it might be achieved.
Review in Nature, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 103 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
103 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Time to HIV viral rebound and frequency of post-treatment control after analytical interruption of antiretroviral therapy: an individual data-based meta-analysis of 24 prospective studies.Nature communications · 2025Pooled it
- The Impact of Antiretroviral Therapy on Neurocognitive Outcomes Among People Living with HIV in Low- and Middle-Income Countries (LMICs): A Systematic Review.AIDS and behavior · 2021Pooled it
- Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study.The lancet. HIV · 2024Trial
- Circulating immune and plasma biomarkers of time to HIV rebound in HIV controllers treated with vesatolimod.Frontiers in immunology · 2024Trial
- Trial
- Stress and Coping During an HIV Cure-Related Trial with an Analytical Treatment Interruption: A Qualitative Assessment of the Experiences of Young Women in Durban, South Africa.Journal of the International Association of Providers of AIDS CareTrial
- Deceiving HIV: Engineered erythrocytes as cellular decoys.Molecular therapy. Advances · 2026Article
- Early intervention, lasting impact: benefits of early antiretroviral therapy and implications for posttreatment control.Current opinion in HIV and AIDS · 2026Review
- Boosting SIV-specific CD8+ T cell responses prior to ART interruption extends time to SIVmac239 rebound.The Journal of clinical investigation · 2026Article
- Broadly neutralizing antibody-secreting CAR-T cells elicit Fc-mediated effector functionsFrontiers in immunology · 2026Article
- Impact of analytical treatment interruptions on sexual behaviors: a mixed-methods longitudinal study of women enrolled in an HIV cure-related trial in Durban, South Africa.HIV research & clinical practice · 2025Article
- CEST MRI assessment of HIV-1-associated neurometabolic impairments in a humanized mouse model.NeuroImmune pharmacology and therapeutics · 2025Article
- Learning from nature: HIV elite controllers as blueprints for a functional cure.Virology journal · 2025Review
- 'It is scary to pause treatment': perspectives on HIV cure-related research and analytical treatment interruptions from women diagnosed during acute HIV in Durban, South Africa.HIV research & clinical practice · 2025Article
- The role of analytical treatment interruptions in shaping HIV-specific immunity and HIV cure.Current opinion in HIV and AIDS · 2025Review
- Integrating socio-behavioral, ethics, community, and translational science considerations in HIV cure research.Current opinion in HIV and AIDS · 2025Review
- Understanding of HIV cure research in a rural community with high prevalence: the case of uMkhanyakude district, KwaZulu-Natal, South Africa.AIDS research and therapy · 2025Article
- Mild HIV-specific selective forces overlaying natural CD4+ T cell dynamics explain the clonality and decay dynamics of HIV reservoir cells.Cell systems · 2025Article
- The global burden, trends, and inequalities of HIV/AIDS: a multicountry observational analysis.BMC infectious diseases · 2025Observational
- Article
43 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
3 authors.
Funding
Abstract
Despite considerable global investment, only 60% of people who live with HIV currently receive antiretroviral therapy. The sustainability of current programmes remains unknown and key incidence rates are declining only modestly. Given the complexities and expenses associated with lifelong medication, developing an effective curative intervention is now a global priority. Here we review why and where a cure is needed, and how it might be achieved. We argue for expanding these efforts from resource-rich regions to sub-Saharan Africa and elsewhere: for any intervention to have an effect, region-specific biological, therapeutic and implementation issues must be addressed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.